Suggested remit: To appraise the clinical and cost effectiveness of finerenone within its marketing authorisation for treating heart failure with preserved or mildly reduced ejection fraction.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6514
Provisional Schedule
- Committee meeting: 1:
- 08 April 2026
- Expected publication:
- 04 June 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Bayer plc (finerenone)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Pumping Marvellous Foundation
- Professional groups
- British Cardiovascular Society
- British Society for Heart Failure
- Primary Care Cardiovascular Society
- Royal College of Physicians
- UK Clinical Pharmacy Association
- Associated public health groups
- None
- Comparator companies
- AstraZeneca (dapagliflozin) (confidentiality agreement signed, participating)
- Boehringer Ingelheim (empagliflozin) (confidentiality agreement signed, participating)
- Accord Healthcare (furosemide) (confidentiality agreement not signed, not participating)
- ADVANZ Pharma (furosemide) (confidentiality agreement not signed, not participating)
- AS Kalceks (furosemide) (confidentiality agreement not signed, not participating)
- Baxter Healthcare (furosemide) (confidentiality agreement not signed, not participating)
- Hameln Pharmaceuticals (furosemide) (confidentiality agreement not signed, not participating)
- Ipca Laboratories UK (furosemide) (confidentiality agreement not signed, not participating)
- Mylan (bumetanide, torasemide) (confidentiality agreement not signed, not participating)
- Pinewood Healthcare (furosemide) (confidentiality agreement not signed, not participating)
- Rosemont Pharmaceuticals (bumetanide, furosemide) (confidentiality agreement not signed, not participating)
- Thame Laboratories (furosemide) (confidentiality agreement not signed, not participating)
- Tillomed Laboratories (furosemide) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- None
Related links
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 28 August 2025 | Invitation to participate |
| 29 April 2025 - 29 May 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6514 |
| 29 April 2025 | In progress. Scoping commencing |
| 16 April 2025 | Referral |
| 14 November 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual